Skip to Main Content

++

INTRODUCTION

++

anidulafungin (a-ni-du-la-fun-gin)

Eraxis

Classification

Therapeutic: antifungals

Pharmacologic: echinocandins

++
Indications
++

Candidemia and other serious candidal infections including intra-abdominal abscess, peritonitis. Esophageal candidiasis.

++
Action
++

Inhibits the synthesis of fungal cell wall. Therapeutic Effects: Death of susceptible fungi. Spectrum: Active against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis.

++
Adverse Reactions/Side Effects
++

Resp: dyspnea. CV: hypotension. GI: diarrhea, ↑ liver enzymes. Derm: flushing, rash, urticaria. F and E: hypokalemia.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Assess blood pressure periodically, and compare to normal values (See Appendix F). Report low blood pressure (hypotension), especially if patient experiences dizziness, fatigue, or other symptoms.

  • Monitor any muscle weakness, aches, or cramps that might indicate low potassium levels (hypokalemia). Report prolonged or excessive muscle problems to the physician.

  • Monitor respiratory function at rest and during exercise. Report difficult or labored breathing (dyspnea) to the physician.

++
Interventions
++

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Use universal precautions or isolation procedures as indicated for specific patients.

++
Patient/Client-Related Instruction
++

  • Instruct patient to report other troublesome side effects such as prolonged or severe diarrhea or skin reactions (rash, hives, itching, flushing).

++
Pharmacokinetics
++

Absorption: IV administration results in complete bioavailability.

++

Distribution: Crosses the placenta.

++

Metabolism and Excretion: Undergoes chemical degradation without hepatic metabolism; <1% excreted in urine.

++

Half-life: 40–50 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (blood levels)

ROUTE ONSET PEAK DURATION
IV rapid end of infusion 24 hr

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity.

++

Use Cautiously in: Underlying liver disease (may worsen); OB: Pregnancy or lactation (use only if benefits outweigh potential risk; Pedi: Safe use in children not established.

++
Interactions
++

Drug-Drug: None noted.

++
Route/Dosage
++

IV (Adults): Esophageal candidiasis—100 mg loading dose on day 1, then 50 mg daily. Candidemia and other candidal infections—200 mg loading dose on day 1, then 100 mg daily.

++
Availability
++

Lyophilized powder for IV use (requires reconstitution): 50 mg/vial

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.